Table 2

Risk of GORD and PPI use among hormone replacement therapy users: simple regression
All hormone users Oestrogen-only users Tibolone users Combined HRT users Progestogen users
No. of hormone users Unmatched cohort 22101 9137 7678 1539 3747
Matched1cohort 2777 950 167 1190 470
GORD OR (95%CI) p Unmatched cohort 1.23 (1.18–1.27) <0.001 1.36 (1.29–1.43) <0.001 1.26 (1.23–1.51) <0.001 1.15 (1.09–1.20) <0.001 1.11 (1.04–1.20) 0.040
Matched cohort 1.29 (1.12–1.48) <0.001 1.59 (1.27–2.0) <0.001 1.14 (1.06–1.22) <0.001 1.14 (0.92–1.43) 0.234 1.15 (1.06–1.23) <0.001
PPI2 OR (95%CI) 3p Unmatched cohort 1.38 (1.19–1.60) <0.001 1.46 (1.16–1.84) 0.001 1.52 (0.92–2.50) 0.100 1.41 (1.10–1.80) 0.006 1.06 (0.71–1.59) 0.760
Matched cohort 1.30 (1.15–1.52) 0.001 1.42 (1.10–1.84) 0.007 1.38 (0.48–3.95) 0.549 1.21 (0.95–1.54) 0.121 1.18 (0.72–1.95) 0.512

1. Uses and non-users were matched according to calendar year, age at menopause, socio-economic status of GP practice, and date closest to menopause.

2. Ever PPI use within study window.

3. P-values: comparison of binary variables by adjusted χ2 test; continuous variables by Student’s t-test; multiple category variables by χ2 test adjusted for trend.

Close et al.

Close et al. BMC Gastroenterology 2012 12:56   doi:10.1186/1471-230X-12-56

Open Data